

HERPESVIRUS

CLINICAL, PHARMACOLOGICAL AND BASIC ASPECTS

Editors

Hiroshi Shiota

Yung-Chi Cheng

William H. Pruseff

HERPESVIRUS

Clinical, Pharmacological and Basic Aspects

Proceedings of the International Symposium on
Herpesvirus held in Tokushima City, Japan,
July 27–30, 1981

Editors

Hiroshi Shiota

Tokushima University, Tokushima, Japan

Yung-Chi Cheng

University of North Carolina, Chapel Hill, NC, U.S.A.

William H. Prusoff

Yale University, New Haven, CT, U.S.A.



1982

Excerpta Medica, Amsterdam-Oxford-Princeton

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without permission in writing from the publisher.

International Congress Series No. 571

ISBN Excerpta Medica 90 219 0519 1

ISBN Elsevier Science Publishing Co. 0 444 90248 1

Library of Congress Cataloging in Publication Data

Main entry under title:

Herpesvirus : clinical, pharmacological, and basic aspects.

"International Symposium on 'Herpesvirus: Clinical, Pharmacological, and Basic Aspects'"--

Includes indexes.

1. Herpesvirus diseases--Congresses. 2. Herpesviruses--Congresses. I. Shiota, Hiroshi, 1943-
II. Cheng, Yung-Chi. III. Prusoff, William Herman, 1920- . IV. International Symposium on "Herpesvirus: Clinical, Pharmacological, and Basic Aspects" (1981 : Tokushima-shi, Japan) [DNLM: 1. Herpesviridae--Congresses. 2. Herpesvirus infections--Congresses. W3 EX89 no. 571 1981 / QW 165.5:H3 H563 1981] RC147.H6H47 616.9'25 82-4981
ISBN 0-444-90248-1 AACR2

Publisher:

Excerpta Medica
305 Keizersgracht
P.O. Box 1126
1000 BC Amsterdam

Sole Distributors for the USA and Canada:

Elsevier Science Publishing Co., Inc.
52 Vanderbilt Avenue
New York, N.Y. 10017

International Symposium on Herpesvirus: Clinical, Pharmacological and Basic Aspects

Organizing Committee

Organizers: Hiroshi Shiota
Yung-Chi Cheng
William H. Prusoff

Secretaries: Osamu Tamura
Shinta Yamane

Treasurer: Sumiko Inoue

Sponsored by

The Association for Research in Infectious Diseases of the Eye, Japan

President: Yukihiro ~~Mitsui~~ **Mitsui**

Vice-President: Shusaku **Kitano**

Members of Board: Yukio **Uchida**

Naohiko **Tanaka**

Shunsaku Kobayashi

Hisaya Tokuda

Masao Ooishi

Kohkichi Shimada

Jiro Hara

Hiroshi Shiota



Sightseeing at Naruto - July 28th, 1981

PREFACE

We are very glad that this International Symposium on Herpesvirus could be held in the beautiful country city of Tokushima rather than in a big city like Tokyo. Fortunately, many participants could attend the Symposium, even though the trip to Tokushima is rather difficult.

We were overwhelmed by hearing so many excellent papers at the Symposium. Accordingly, it seemed appropriate that this important material should be published to make it thus more widely available. We thank all the speakers for their cooperation and for sending their manuscripts for publication.

We are very happy that the Proceedings have now been completed and are available. We hope that they will be useful in clinical, pharmacological and basic fields and provide valuable information for future studies on herpesviruses.

Hiroshi Shiota
Yung-Chi Cheng
William H. Prusoff

OPENING REMARKS

It is a great pleasure for us to have the International Symposium on 'Herpesvirus: Clinical, Pharmacological and Basic Aspects' here in Tokushima. As you all know, this is a Satellite Symposium of the 8th International Congress of Pharmacology which was held in Tokyo last week. At this Symposium, pharmacologists, clinicians and virologists can get together to discuss herpesvirus-induced diseases. Usually, pharmacologists have their own congresses and we, clinicians, have our own congresses separately. But here, three types of specialists, pharmacologists, virologists and clinicians, can meet and discuss in detail all overlapping interests. This is one of the most important aspects of this Symposium.

Many foreign speakers as well as Japanese speakers are present. In particular, I wish to mention three outstanding scientists: Professor Prusoff, one of the organizers of this Symposium, synthesized 5-iodo-2'-deoxyuridine (IDU) in 1959. Until then we did not have any effective antivirals. Professor Kaufman of the United States proved IDU to be effective against herpetic keratitis in 1962. Since then it has been used all over the world and is now regarded as the drug of choice in the treatment of herpes simplex virus infections. But, as you all know, although IDU is effective, it has some toxic reactions. However, Dr. Elion and her team synthesized a new compound, called acyclovir, which is a guanine derivative. They found that it has very low toxicity and so can be used systemically. We are delighted to have these three doctors, who established milestones in medical virology, here with us. And not only these three doctors, but many other outstanding specialists are taking part in this Symposium. I would like to thank them very much for attending and I hope that this Symposium will provide you all with important information to combat viral diseases.

Finally, I would like to mention three more doctors who have helped to make this Symposium possible. First of all, Professor Kamesaburo Yoshino of Tokyo University. Professor Yoshino is a pioneer in herpes studies in Japan. Unfortunately he could not come to this Symposium because of another meeting. It was he who selected the main speakers from Japan and gave me his excellent advice. The second one is Professor Uchida of the Virology Department of Tokushima University, who kindly assisted me and gave me his encouragement. The third is Professor Mitsui, President of the Association for Research in Infectious Diseases of the Eye in Japan, who supported this symposium financially and mentally, and encouraged me in every respect.

I hope that all of you will have a very good time in Tokushima and that you will find the Symposium useful as regards the combat against herpesvirus-induced diseases.

Hiroshi Shiota

CONTENTS

Opening remarks

H. Shiota

ix

I. MORPHOLOGY

Transmission and scanning electron microscopic studies of herpes viruses

S. Nii

3

Molecular structure of herpesvirus papio DNA and cloning of its repeat sequence in plasmid pACYC 184

Y.S. Lee, M. Nonoyama and H. Rabin

12

II. LATENCY

Herpesvirus infection and its effect on virulent superinfection, ganglionic colonization, and shedding

E.D. Varnell, Y.M. Centifanto-Fitzgerald and H.E. Kaufman

21

Gangliosides from the brains of mice experimentally infected with herpes simplex virus, type I

T. Abe, M. Hiraiwa, K. Ogawa, H. Fujiwara, Y. Tokoro, A. Yamamoto, T. Kurata and Y. Aoyama

25

Induction of a transforming agent(s) by abortive infection of herpes simplex virus in the cells carrying endogenous sarcoma virus

Y. Shimizu and K. Kumagai

29

Replication of herpes simplex virus on two bat cell lines

M. Yamada, F. Uno, K. Akatsuka and S. Nii

34

III. IMMUNOLOGY

Successful passive transfer between inbred experimental mice of spleen cells immune to herpetic keratitis

H. Saito, T. Sasaki and N. Tanaka

41

IV. BIOCHEMISTRY

Herpes virus specific enzymes: properties, physiological roles, and pharmacological implications

Y.-C. Cheng, K. Nakayama, D. Derse, K. Bastow, J. Ruth, R.-S. Tan, G. Dutchman, S.J. Caradonna and S. Grill

47

| | |
|--|----|
| The HSV-1 thymidine kinase gene controls expression in eukaryotic and prokaryotic cells and viral pathogenesis in mice <i>Y. Becker, Y. Shtram, D. Snipper, Y. Asher, E. Tabor, Y. Gordon, D. Gilden, M. Wellish, J. Hadar, O. Becker, A. Cohen, A. Laban and A. Honigman</i> | 57 |
| Conformation of nucleosides and nucleotides, role in some enzymatic reactions, and relevance to design of antitumour and antiviral agents <i>D. Shugar, R. Stolarski and L. Dudycz</i> | 74 |

V. VARICELLA-ZOSTER VIRUS

| | |
|--|-----|
| Application of a live varicella vaccine in children with acute leukemia <i>M. Sakurai, T. Ihara, M. Ito, S. Hirai, T. Iwasa, K. Oitani, H. Kamiya, T. Izawa and M. Takahashi</i> | 87 |
| Comparative efficacy of antiherpes drugs against different strains of varicella-zoster virus <i>S. Shigeta, T. Yokota, M. Ogata, K. Abe and E. de Clercq</i> | 94 |
| IGM to varicella-zoster virus during health and disease <i>A.A. Gershon, S.P. Steinberg, W. Borkowsky, D. Lennette and E. Lynette</i> | 98 |
| Mutant strain of varicella-zoster virus deficient in thymidine kinase-inducing activity <i>T. Yokota, S. Shigeta, T. Iwabuchi, M. Ogata and Z. Takami</i> | 102 |
| Humoral and cellular immunity in herpes zoster <i>O. Urushibata, F. Saito and T. Simbo</i> | 106 |
| Clinical trial of a low molecular weight co-polymer of 3-germyl propionic acid sesquioxide, in the treatment of viral diseases with cutaneous manifestations <i>M. Morioka and S. Toyoshima</i> | 110 |

VI. ANTIVIRAL AGENTS

| | |
|---|-----|
| Alkyldeoxyuridines: pharmacology and clinical experiences <i>K.K. Gauri</i> | 117 |
| Adenine arabinoside (ara-A) therapy of herpes virus infections in humans <i>R. Dolin and R.C. Reichman</i> | 129 |
| Chemistry and potent antiviral activity of 2'-fluoro-5-substituted-arabinosyl-pyrimidine-nucleosides <i>J.J. Fox, K.A. Watanabe, C. Lopez, F.S. Philips and B. Leyland-Jones</i> | 135 |
| Chemotherapy on herpes virus, particularly the effect of antiviral amino acid analogues <i>S. Toyoshima, M. Fukuma, H. Fujita and Y. Seto</i> | 148 |
| E-5-(2-bromovinyl)-2'-deoxyuridine (BVDU), pharmacology and clinical experience <i>I.S. Sim, D.M. Meredith, J. Nuttall and K.G. McCullagh</i> | 157 |

| | |
|--|-----|
| In vitro and in vivo anti-HSV activities of 1- β -D-arabinofuranosyl-E-5-(2-halogenovinyl)uracil | |
| <i>H. Machida, S. Sakata, A. Kuninaka and H. Yoshino</i> | 165 |
| Preclinical evaluation of the herpesvirus inhibitor foscarnet sodium | |
| <i>B. Öberg, S. Alenius, B. Eriksson, E. Helgstrand, C. Lundberg and J. Lundström</i> | 175 |
| Foscarnet sodium (trisodium phosphonoformate) in treatment of recurrent herpes infections | |
| <i>J. Wallin, J.-O. Lernestedt and E. Lycke</i> | 179 |
| Antitherpetic chemotherapy in China | |
| <i>H.-S. Chen and P.-Y. Tien</i> | 183 |
| Prostaglandins and the replication of herpes simplex type 1 | |
| <i>A.A. Newton</i> | 192 |
| Iontophoretic application of antiviral drugs | |
| <i>L.P. Gangarosa Sr., H.J. Park, B.S. Kwon and J.M. Hill</i> | 201 |
| Drug resistance in herpes simplex virus | |
| <i>H.J. Field</i> | 205 |
| Selectivity of antiherpes compounds on viral and cellular DNA synthesis | |
| <i>A. Larsson and B. Öberg</i> | 211 |
| Anti-herpes simplex virus (HSV) activities of some purine arabinosides in vitro | |
| <i>S. Inoue and H. Shiota</i> | 215 |
| Safety of 1- β -D-arabinofuranosylthymine in toxicity and teratogenicity in rats | |
| <i>K. Saito, H. Machida, A. Kuninaka, H. Yoshino, M. Miyasaka, H. Kawamura and R. Ito</i> | 219 |
| Susceptibility of several strains of varicella-zoster virus to 5-substituted derivatives of 2'-deoxyuridine and 1- β -D-arabinofuranosyluracil | |
| <i>H. Machida, A. Kuninaka and H. Yoshino</i> | 223 |

VII. OCULAR HERPES

| | |
|--|-----|
| Mechanism of action, pharmacology and clinical efficacy of acyclovir | |
| <i>G.B. Elion</i> | 229 |
| Clinical manifestations of herpetic keratitis | |
| <i>N. Tanaka</i> | 236 |
| Clinical trial of acyclovir on herpetic keratitis | |
| <i>H. Shiota</i> | 243 |
| Studies on immunotherapy for the herpetic stromal keratitis with levamisole | |
| <i>S. Ohno, F. Kato and H. Matsuda</i> | 250 |
| A clinical evaluation of herpetic keratitis with 0.01% phosphonoacetic acid solution for the treatment of humans | |
| <i>I. Mikuni, T. Fujiwara, K. Samizo, K. Hirai, N. Mizushima and K. Togawa</i> | 262 |
| Idoxuridine-resistant herpes simplex virus isolated from bilateral geographic corneal ulcers | |
| <i>M. Isobe, M. Yoshida and H. Taniguchi</i> | 266 |

| | |
|---|-----|
| Selection of antiviral agents for clinical use: acyclovir | |
| <i>H.E. Kaufman</i> | 270 |

VIII. INTERFERON

| | |
|---|-----|
| Interferon as an antiherpes agent in man | |
| <i>M. Ho</i> | 277 |
| Preparation of human fibroblast interferon (Hu IFN- β) | |
| <i>S. Kobayashi, M. Iizuka, M. Hara, H. Ozawa, T. Nagashima and J. Suzuki</i> | 286 |
| The effect of human fibroblast interferon on herpetic keratitis in rabbits | |
| <i>H. Shiota and S. Yamané</i> | 295 |
| Therapeutic effect of human fibroblast interferon on herpes simplex keratitis | |
| <i>Y. Uchida</i> | 302 |
| A general summary on our interferon studies | |
| <i>R. Sundmacher</i> | 308 |
| Interferon and interferon inducer myroridin K as an immunomodulator in herpes simplex virus infection | |
| <i>K. Kumagai, I. Kurane, K. Itoh, F. Saito and Y. Tsuchiya</i> | 311 |
| Protective effects of IFN, various anti-viral drugs and combinations of these on herpes simplex virus infection in mice | |
| <i>M. Matsubara, H. Yasuno, J. Imanishi and T. Kishida</i> | 321 |

IX. HERPETIC ENCEPHALITIS

| | |
|--|-----|
| Herpes simplex encephalitis | |
| <i>H. Shoji</i> | 327 |
| Two autopsy cases of long-surviving herpes simplex virus encephalitis treated with adenine arabinoside – Pathologic, immunofluorescent, and electron-microscopic studies | |
| <i>S. Kamei, T. Takasu, T. Shikata, K. Akai, Y. Aoyama and T. Kurata</i> | 331 |

X. GYNECOLOGICAL HERPES

| | |
|---|-----|
| Clinical and virological aspects of female genital herpes in Japan | |
| <i>T. Kawana, J.T. Chen, H. Yoshikawa, R. Yoshida, M. Nagano and S. Sakamoto</i> | 339 |
| Preliminary study on the role of co-factors in inducing cervical cancer in mice by genital herpes simplex virus | |
| <i>M.-H. Chen and Y. Swen</i> | 351 |
| Experimental studies on induction of cervical carcinoma in mice by genital herpes simplex virus | |
| <i>M.-H. Chen and Y. Swen</i> | 358 |

XI. EPSTEIN-BARR VIRUS AND NASOPHARYNGEAL CARCINOMA

| | |
|---|-----|
| Epstein-Barr virus-activating principles in medicinal plants | |
| <i>Y. Ito, M. Kishishita, S. Yanase and T. Harayama</i> | 373 |
| Persistent active infection of Epstein-Barr virus (EBV) in carrier females of the X-linked lymphoproliferative syndrome (XLP) | |
| <i>K. Sakamoto, J.K. Seeley and D.T. Purtilo</i> | 375 |
| Serological studies on nasopharyngeal carcinoma and cervical cancer in China | |
| <i>Y. Zeng</i> | 380 |
| Immunology and diagnosis of nasopharyngeal carcinoma | |
| <i>J.H.C. Ho, W.H. Lau, H.C. Kwan, C.L. Chan, G.H.K. Au and D. Saw</i> | 389 |
| Nasopharyngeal carcinoma and cervical carcinoma in Taiwan, China | |
| <i>T.M. Lin</i> | 398 |
| Treatment of nasopharyngeal carcinoma | |
| <i>T.-C. Lynn, S.-C. Huang and S.-M. Tu</i> | 408 |
| A preliminary study on the anti-EBV-specific DNase activities of nasopharyngeal carcinoma (NPC) patients' sera | |
| <i>Q. Pan, D. Huang, W. Luo, X. Jiao, J. Chen and L. Chen</i> | 418 |
| Epstein-Barr virus activation with Euphorbiaceae plant extracts: a possible cause for Burkitt's lymphoma and nasopharyngeal carcinoma | |
| <i>Y. Ito, S. Yanase, T. Morigaki and M. Kishishita</i> | 423 |
| Transplantability of two Marek's disease virus associated lymphoblastoid cell lines (MSB-1-41C and MSB-1-33C) | |
| <i>H. Matsuda, M. Yamada, F. Uno and S. Nii</i> | 424 |
| Recent and future developments in antiviral chemotherapy | |
| <i>W.H. Prusoff, M.S. Chen, J.-J. Shim Lee, T.-S. Lin, W.R. Mancini, M.J. Otto and J. Spivack</i> | 428 |
| Closing remarks | |
| <i>W.H. Prusoff</i> | 437 |
| List of participants | 439 |
| Index of authors | 445 |
| Subject index | 449 |

TRANSMISSION AND SCANNING ELECTRON MICROSCOPIC STUDIES OF HERPES VIRUSES

Shiro Nii

Department of Virology, Okayama University Medical School,
Okayama, Japan

INTRODUCTION

Numerous electron microscopic studies on herpesviruses have so far been presented and at least two excellent reviews, namely by Watson (1973) (9) and by O'Callaghan and Randall (1976) (6) dealt with the morphogenesis of these viruses. For more than 15 years we have been engaged in electron microscopic studies on various herpesviruses, first to reveal their maturation process and second to clarify ultrastructural pathology of cells infected with these viruses. This report is concerned with some of our experimental results related to this research.

ULTRASTRUCTURE OF VIRIONS OF HERPESVIRUSES

In thin sections most virions of herpesviruses appear as spherical particles of an oval or round electron dense core, a capsid surrounding the core and an envelope enclosing the capsid, as illustrated by one particle of type 1 herpes simplex virus (HSV-1) shown in Fig. 1. Occasionally, the tegument, defined as the structure located between the capsid and the envelope (7), is prominently visible, and a typical example is the virion of turkey herpesvirus shown in Fig. 2. The amount of this material is variable according to the kind of herpesvirus and also from virion to virion of any given herpesvirus.

Furlong et al. (1972) (1) hypothesized that the core of the herpes simplex virion consists of an electron-dense toroidal structure penetrated by a less dense cylindrical mass. It should be kept in mind, however, that the morphological appearance of the core varies, being highly dependent on the kind and method of fixation (2). The hypothesis of Furlong et al. developed from observations of infected cell material prepared by fixation in 2.5% glutaraldehyde in phosphate buffer (pH 7.2). When cells productively infected with any given herpesvirus were prefixed with this kind of fixative with or without a slight modification and postfixed with Millonig's fixative, capsids enclosing a toroid structure were easily detectable in the nucleus. In fact we observed the structure





Figure 1. A virion of type 1 herpes simplex virus. x 140,000

Figure 2. A virion of turkey herpesvirus with abundant tegument material seen in the rough-surfaced endoplasmic reticulum. x 73,500





Figure 3. A capsid with a toroid structure detected in a nucleus infected with Marek's disease virus. Fixation: pre-fixation with 1% glutaraldehyde in Sørensen's phosphate buffer and post-fixation with Millonig's fixative. x 170,000

Figure 4. A virion of type 1 herpes simplex virus. The core appears to consist of an electron-dense ball of twine. Fixation: prefixation with 1.5% glutaraldehyde in 0.16 M cacodylate buffer and post-fixation with 1% osmium tetroxide in 0.1 M s-collidine buffer. x 150,000

with eight herpesviruses examined (3). Fig. 3. shows a toroid structure in a capsid found in a nucleus infected with Marek's disease virus.












On the other hand, when infected cells were prefixed with glutaraldehyde in cacodylate buffer and postfixed with osmium tetroxide in s-collidine buffer, toroids could no longer be found and instead viral cores resembling an electron-dense ball of twine were observed (Fig. 4). This morphological appearance of the core, which was also observed by Heine and Cottler-Fox (1974) with one of five fixing and *en bloc* staining procedures examined (2), may demonstrate an ultrastructure closer to the native one.

MORPHOLOGICAL VARIABILITY OF INTRANUCLEAR VIRUS PARTICLES CORRELATED WITH THEIR DEVELOPMENT

Capsids with variable appearance of cores were easily detectable in the nuclei of cells infected with any given herpesvirus and this variation in morphology was thought to be mainly caused by the difference in their developmental stages.

To clarify this problem time-sequence electron microscopic examinations of cells infected with type 2 herpes simplex virus (HSV-2) were performed. FL cells were infected with the syn⁺ and syn⁻ variants of the UW 268 strain at an adsorbed multiplicity of approximately 10 and fixed 4, 6 and 8 hrs later. The fixatives used were 1% glutaraldehyde in phosphate buffer for prefixation and Millonig's fixative for postfixation. The following results were obtained. Intranuclear particles appeared as early as 4 hrs after infection and rapidly increased in number, while enveloped particles and budding particles were found 6 hrs after infection. The frequencies of various viral forms in the nuclei at each time were

TABLE 1. Different intranuclear viral forms and frequency of their appearance at earlier periods after infection.

| Virus | Hours after infection |  |  |  |  |  |  |  |  |  |  |  |
|---------------------------|-----------------------|---|---|---|---|---|---|---|---|---|---|---|
| UW268 Syn ⁺ | 4 | 7% | 3% | 47% | 0% | | 40% | | 0% | | 3% | |
| | 6 | 5% | 2% | 33% | 2% | | 30% | | 6% | | 23% | |
| | 8 | 5% | 3% | 29% | 7% | | 18% | | 4% | | 35% | |
| UW268 Syn ⁻ | 4 | 2% | 4% | 69% | 0% | | 22% | | 0% | | 3% | |
| | 6 | 4% | 4% | 27% | 1% | | 43% | | 2% | | 19% | |
| | 8 | 1% | 1% | 37% | 3% | | 20% | | 1% | | 35% | |